FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/082046 [Registered on: 10/03/2025] Trial Registered Prospectively
Last Modified On:
Post Graduate Thesis  No 
Type of Trial  PMS 
Type of Study   Other (Specify) [Cosmetics]  
Study Design  Single Arm Study 
Public Title of Study   Eye irritation test of Zydus EqualsTwo Body Wash  
Scientific Title of Study   A Clinical Study to Evaluate the Eye Stinging Potential of Zydus EqualsTwo Body Wash on Healthy Human Volunteers 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
CCFT527 Version 1.0 dated 18 Feb 2025  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ishika Gandhi  
Designation  Principal Investigator 
Affiliation  CCFT Laboratories 
Address  1st Floor room 3, Skin testing lab , CCFT laboratories, AR multispecialty hospital and research center, Delhi Road

Meerut
UTTAR PRADESH
250002
India 
Phone  9868965688  
Fax    
Email  ishika02gandhi@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Puneet Mittal  
Designation  Clinical Research Consultant 
Affiliation  CCFT Laboratories  
Address  1st Floor room 3, Skin testing lab , CCFT laboratories, AR multispecialty hospital and research center, Delhi Road

Meerut
UTTAR PRADESH
250002
India 
Phone  8937015757  
Fax    
Email  puneetmittal@mgcts.org   
 
Details of Contact Person
Public Query
 
Name  Puneet Mittal  
Designation  Clinical Research Consultant 
Affiliation  CCFT Laboratories  
Address  1st Floor room 3, Skin testing lab , CCFT laboratories, AR multispecialty hospital and research center, Delhi Road


UTTAR PRADESH
250002
India 
Phone  8937015757  
Fax    
Email  puneetmittal@mgcts.org   
 
Source of Monetary or Material Support  
CCFT Laboratories, 135, Punjabipura, Delhi Road, Meerut, India 250002  
Zydus Life Sciences Limited, Plot no-265,266,267 oppostie Laxaminarayan Petrol Pimp, Sarkhej, Amhedabad- 382210 
 
Primary Sponsor  
Name  Zydus Life Sciences Limited 
Address  Plot no-265,266,267 oppostie Laxaminarayan Petrol Pimp, Sarkhej, Amhedabad- 382210 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
Not Applicable  Not Applicable 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ishika Gandhi  CCFT laboratories  First Floor room 1, CCFT laboratories, AR multispecialty hospital and research center, Delhi Road
Meerut
UTTAR PRADESH 
9027285265

ishika02gandhi@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
ARMHRC Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Not Applicable 
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Not Applicable  Not Applicable 
Intervention  Test Product: Equals two Body Wash  Dose: Approx 5 microliter Route: in eyes(on the lower sac) Frequency: Once Duration: 5 mins  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1.Healthy males or females, 18 to 60 years with no medical conditions of the eyes as determined by the subjects medical history and confirmed by an ophthalmologist
2. Subjects not under any doctor care for ocular or peri orbital diseases
3. The subject will refrain from using contact lenses, any topical facial products, any eye drops, false eyelashes, make up, over the counter products, or cosmetics on their eyes, eyelids, eyelashes, or the periorbital areas of the face during the study.  
 
ExclusionCriteria 
Details  1.Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study.
2.Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition.
3.Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product.
4.Have participated in any interventional clinical trial in the previous 30 days.
5.Have a known sensitivity to any of the constituents of the test product including sensitivities to cocoamidopropyl betaine, coumarin, Aloe barbadensis etc.
6.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids.
7.Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Change in lacrimation
 
0min, 1min, 5min  
 
Secondary Outcome  
Outcome  TimePoints 
Change in conjunctival inflammation   0min, 1min, 5min  
Change in cornea and iris inflammation   0min, 1min, 5min  
Change in Subject Discomfort   0min, 1min, 5min  
 
Target Sample Size   Total Sample Size="32"
Sample Size from India="32" 
Final Enrollment numbers achieved (Total)= "0"
Final Enrollment numbers achieved (India)="0" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   19/03/2025 
Date of Study Completion (India) Date Missing 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="0"
Days="2" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
single arm clinical study.
5 μL of the appropriate test should be instilled into the lower conjunctival sac of one eye, and another eye should be instilled with Normal Saline as Negative control. No Positive control to be taken.
Assessment would be done as 5-point scale for the below attributes after 1 min/2 min/5 min.
1.
Subjective discomfort,
Score 0: No discomfort felt Score 1: Faint, barely perceptible discomfort Score 2: Mild, low intensity discomfort that does not prevent the subject from opening lids Score 3: Moderately intense discomfort that interferes with but does not prevent lid opening Score 4: Severe, very intense discomfort that makes voluntary lid opening difficult, requires force to pull lids apart, and results in the subject requesting washout of test article
2.
Objective lacrimation,
Score 0: No tearing or lid wetness above normal Score 1: Noticeable increase in moistness of lid edges - no frank tearing Score 2: Frank tearing - meager flow Score 3: Frank tearing - moderate flow Score 4: Frank tearing - copious flow
3. Objective conjunctival inflammation,
Score 0: Inflammatory changes absent Score 1: Capillaries slightly more prominent than they were at time of baseline examination Score 2: Capillaries very prominent plus some diffuse conjunctival reddening Score 3: Vessels very prominent plus diffuse and confluent intense redness Score 4: Beefy redness and everted lids
4. Objective cornea and iris inflammation
Score 0: No effect detected with use of slit lamp Score 1: Barely perceptible clouding or pitting of cornea or thickening of iris detected via slit lamp Score 2: Faint clouding or pitting of cornea and/or thickening of the iris Score 3: Moderate clouding or pitting of cornea and/or thickening of the iris Score 4: Intense clouding orpitting of cornea and/or thickening of the iris
A follow-up visit is done after 24 hours to assess any adverse effect after the Product application
 
Close